Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN AND DIPHENHYDRAMINE CITRATE versus ONMEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN AND DIPHENHYDRAMINE CITRATE versus ONMEL.
IBUPROFEN AND DIPHENHYDRAMINE CITRATE vs ONMEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing pain, fever, and inflammation. Diphenhydramine citrate is an antihistamine that antagonizes histamine H1 receptors, producing sedative and anticholinergic effects.
ONMEL (omacetaxine mepesuccinate) inhibits protein synthesis by binding to the 80S ribosome and interfering with chain elongation, leading to apoptosis in leukemic cells.
Ibuprofen 200 mg + Diphenhydramine citrate 38 mg (equivalent to diphenhydramine HCl 25 mg) orally every 4-6 hours as needed, not to exceed Ibuprofen 1200 mg/day or Diphenhydramine citrate 152 mg/day.
50 mg orally twice daily for 14 days
None Documented
None Documented
Ibuprofen: terminal elimination half-life approximately 1.8-2.5 hours in adults; prolonged in elderly and patients with hepatic impairment. Diphenhydramine: terminal elimination half-life ranges from 4 to 10 hours (mean 7 hours); may be prolonged in elderly and hepatic impairment.
Terminal half-life 40–60 hours (mean 50 hours); allows once-daily dosing for systemic antifungal therapy.
Ibuprofen: renal elimination of metabolites (approximately 90%) and unchanged drug (approximately 10%); fecal elimination <5%. Diphenhydramine: primarily renal elimination (approximately 60-70% as metabolites, 1-2% unchanged); fecal elimination approximately 10-15%.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; >90% eliminated as metabolites in bile and feces.
Category D/X
Category C
NSAID
NSAID